Implications of AD plasma and PET biomarker discordance

IF 28.2 1区医学 Q1 CLINICAL NEUROLOGY

Nature Reviews Neurology Pub Date : 2025-05-01 DOI:10.1038/s41582-025-01091-w

Charlotte E. Teunissen, Lisa Vermunt

引用次数: 0

Abstract

Plasma biomarker tests for Alzheimer disease are becoming increasingly reliable, which enables implementation in clinical settings in which cerebrospinal fluid analysis and PET scans are unavailable. However, a new study shows that some patients have discordant plasma and PET biomarker results. Clinicians need clear guidance to identify and manage patients who do not fit into standard clinical or biological categories.

查看原文本刊更多论文

AD血浆和PET生物标志物不一致的意义

阿尔茨海默病的血浆生物标志物检测正变得越来越可靠，这使得在无法进行脑脊液分析和PET扫描的临床环境中得以实施。然而，一项新的研究表明，一些患者的血浆和PET生物标志物结果不一致。临床医生需要明确的指导来识别和管理不符合标准临床或生物学分类的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Neurology 医学-临床神经学

CiteScore

29.90

自引率

0.80%

发文量

138

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Neurology aims to be the premier source of reviews and commentaries for the scientific and clinical communities we serve. We want to provide an unparalleled service to authors, referees, and readers, and we work hard to maximize the usefulness and impact of each article. The journal publishes Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives relevant to researchers and clinicians working in the field of neurology. Our broad scope ensures that the work we publish reaches the widest possible audience. Our articles are authoritative, accessible, and enhanced with clearly understandable figures, tables, and other display items. This page gives more detail about the aims and scope of the journal.